Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Emerging paradigm: Molecularly targeted therapy with Dabrafenib and Trametinib in recurring pediatric gliomas with BRAF mutations: A narrative review.

Medicine - 6 Dec 2024

Wahid Maryam Abdul, Khan Muhammad Taimur, Hussain Jawairya Muhammad, Malik Hurais, Umar Shahood Ahmed, Mughal Sanila, Hasanain Muhammad, Anjum Muhammad Umair, Mahmmoud Fadelallah Eljack Mohammed

Abstract excerpt

Gliomas are tumors arising in the central nervous system, frequently associated with Class I mutations and BRAF fusions. These mutations are adverse prognostic factors in juvenile gliomas, leading to high rates of recurrence and poor response to current treatments. The blood-brain barrier and the heterogeneity of gliomas complicate the development of a single treatment strategy for all cases. This review aims to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Glioma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imidazoles

Share to Molecular Targeted Therapy

Share to Neoplasm Recurrence, Local

Share to Oximes

Share to Pyridones

Share to Pyrimidinones

Source

Open in PubMed Open full text

Identifiers

PMID: 39654184
DOI: 10.1097/MD.0000000000040735
PMCID: PMC11630983

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Emerging paradigm: Molecularly targeted therapy with Dabrafenib and Trametinib in recurring pediatric gliomas with BRAF mutations: A narrative review.PMID 39654184Read ↗

Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations.Semantic proximity Read ↗

Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600-Mutant Low-Grade Glioma.Semantic proximity Read ↗

Targeted Therapy Win in BRAF-Mutant Gliomas.Semantic proximity Read ↗

Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/Refractory BRAF V600-Mutant Pediatric High-Grade Glioma.Semantic proximity Read ↗

The safety and efficacy of dabrafenib and trametinib in patients with glioma: A systematic review and meta-analysis.Semantic proximity Read ↗

FDA Approval Summary: Dabrafenib in Combination with Trametinib for BRAFV600E Mutation-Positive Low-Grade Glioma.Semantic proximity Read ↗

Clinical response to dabrafenib plus trametinib in a pediatric ganglioglioma with BRAF p.T599dup mutation.Semantic proximity Read ↗

Metastatic Low-Grade Glioma Successfully Treated in a Pediatric Patient With BRAF A598_T599insI Mutation.Semantic proximity Read ↗

Efficacy and Safety of Dabrafenib in Pediatric Patients with <i>BRAF</i> V600 Mutation–Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa StudySemantic proximity Read ↗

Dabrafenib-trametinib is effective in paediatric high-grade glioma.Semantic proximity Read ↗

Significant response to targeted therapy for Cervico-Medullary pediatric low grade glial tumors with BRAF V600E mutationSemantic proximity Read ↗

Rapid Clinical and Radiographic Response With Combined Dabrafenib and Trametinib in Adults With BRAF-Mutated High-Grade Glioma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.